NEW YORK (GenomeWeb News) - Enigma Diagnostics said today that the RANGER Consortium, an international group of companies and research institutes, has received a €3 million ($4.3 million) award from the European Commission Framework 7 program to develop a portable, rapid PCR-based test to detect influenza infections and subtypes.
Enigma, based in Porton Down, UK is the coordinator of the RANGER consortium. Other players include Applied Biosystems, Sagentia, Tico Europe, Bruhn Newtech Group, Bioplastics BV, PERA, the UK’s Health Protection Agency, and the Queen Sirikit National Institute of Child Health.
The company said the diagnostic tool will be based on its automated instrumentation, which integrates sample prep with real-time PCR to detect viral RNA in clinical samples.
Enigma said it is also separately developing RT-PCR-based diagnostic tests for chlamydia, gonorrhea, and other sexually transmitted infections.